What is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company dedicated to the development of pharmaceutically-produced transdermal cannabinoid therapies. The company's primary focus is on addressing rare and near-rare neuropsychiatric disorders. Its lead candidate, Zygel, is a permeation-enhanced gel formulated for transdermal delivery of cannabidiol. Originally incorporated as AllTranz, Inc. in 2007, the company rebranded to Zynerba Pharmaceuticals, Inc. in August 2014 and is headquartered in Devon, Pennsylvania.
How much funding has Zynerba Pharmaceuticals raised?
Zynerba Pharmaceuticals has raised a total of $149.2M across 4 funding rounds:
Unspecified
$13M
Stock Offering
$48.3M
Stock Offering
$58M
Stock Offering
$29.9M
Unspecified (2014): $13M with participation from Perceptive Advisors
Stock Issuance/Offering (2015): $48.3M led by Undisclosed
Stock Issuance/Offering (2017): $58M supported by Undisclosed
Stock Issuance/Offering (2018): $29.9M featuring Undisclosed
Key Investors in Zynerba Pharmaceuticals
Perceptive Advisors
Perceptive Advisors, established in 1999 and based in New York, is an investment firm managing substantial assets, with a strategic focus on backing innovative healthcare and life sciences technologies.
Undisclosed Investors
Undisclosed Investors
What's next for Zynerba Pharmaceuticals?
The substantial enterprise-level funding indicates a strategic push for Zynerba Pharmaceuticals to advance its clinical pipeline, particularly for Zygel. This capital infusion is expected to support further research and development, potentially moving the company towards later-stage trials and regulatory submissions. The focus on rare neuropsychiatric disorders positions Zynerba to address significant unmet medical needs, making future financing rounds or strategic partnerships a likely progression as the company matures.
See full Zynerba Pharmaceuticals company page
